INO Therapeutics Overview

  • Status
  • Acquired/​Merged
  • Employees
  • 463
Employees
  • Latest Deal Type
  • IPO
  • (Cancelled)
  • Financing Rounds
  • 2

INO Therapeutics General Information

Description

Manufacturer of late stage drugs for the treatment of heart and lung functions. The company's primary offering INOmax is used to carry oxygenated blood to the body tissues, and for the treatment of persistant pulmonary hypertension in the newborn.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly PE-Backed
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Acquirer
Primary Office
  • Six State Route 173
  • Clinton, NJ 08809
  • United States
+1 (908) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

INO Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore INO Therapeutics‘s full profile, request access.

Request a free trial

INO Therapeutics Executive Team (2)

Name Title Board Seat Contact Info
Daniel Tassé Chief Executive Officer
David Shaw President
To view INO Therapeutics’s complete executive team members history, request access »

INO Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

INO Therapeutics Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore INO Therapeutics‘s full profile, request access.

Request a free trial